Your browser doesn't support javascript.
loading
Ustekinumab Offers Long-Term Clinical Remission With Safety in Very Early-Onset Inflammatory Bowel Disease.
Iwama, Itaru; Yoshida, Masashi; Miyazawa, Ayako; Hara, Tomoko; Nambu, Ryusuke.
Afiliación
  • Iwama I; Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, Saitama, Japan.
  • Yoshida M; Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, Saitama, Japan.
  • Miyazawa A; Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, Saitama, Japan.
  • Hara T; Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, Saitama, Japan.
  • Nambu R; Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, Saitama, Japan.
Inflamm Bowel Dis ; 30(7): 1220-1222, 2024 Jul 03.
Article en En | MEDLINE | ID: mdl-38588461
We observed efficacy and safety of ustekinumab in very early-onset inflammatory bowel disease, which has not been previously reported. Clinical remission at 52% was 75%, often persisting beyond 2 years. Further studies including larger numbers of cases are needed to confirm this observation.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inducción de Remisión / Enfermedades Inflamatorias del Intestino / Ustekinumab Límite: Humans Idioma: En Revista: Inflamm Bowel Dis Asunto de la revista: GASTROENTEROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inducción de Remisión / Enfermedades Inflamatorias del Intestino / Ustekinumab Límite: Humans Idioma: En Revista: Inflamm Bowel Dis Asunto de la revista: GASTROENTEROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido